These transgenic mice express Cre recombinase under the control of the mouse vav 1 oncogene (Vav1) promoter. The transgene integrated into an intron of Commd10 (COMM domain containing 10) on chromosome 18. The insertion results in a functional knock-out of Commd10 in homozygous mice.
Mice hemizygous for this Vav-iCre transgene are viable and fertile, with the mouse HS21/45-vav control regions directing expression of an optimized variant of Cre recombinase (iCre) to hematopoietic cells (and their progenitors). Using crosses to a reporter strain, variegated germ line (testis and ovaries), and heart and gut expression is also reported. When bred with mice containing a loxP-flanked sequence of interest, Cre-mediated recombination will result in deletion of the floxed sequence(s) in the offspring. These Vav-iCre transgenic mice may be useful for generating conditional mutations in hematopoietic cells.
Joseph et al. 2013 Cell Stem Cell 13:520 reports that Vav-iCre mice express iCre in hematopoietic cells and endothelial cells, as well as in the testes. For Cre-lox experiments and to avoid/minimize germline deletion of the floxed allele, researchers may consider breeding Vav-iCre females with floxed males. However, female germline expression may also be observed (see below).
If the recombinase activity pattern of this allele is further characterized by the Genetic Resource Science group at The Jackson Laboratory, such findings will be reported on the Mouse Genome Informatics (MGI) Allele Detail entry (Commd10Tg(Vav1-icre)A2Kio). This same information would also be found searching the MGI Recombinase Activity database.
This Vav-iCre strain (Stock No. 008610) allows reliable deletion of specific genes throughout the entire hematopoietic compartment, whereas the hCD2-iCre strain (Stock No. 008520) allows targeting to be focused to T cells and B cells.
